BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)
China · Delayed Price · Currency is CNY 57.35
-0.87 (-1.49%)
At close: Apr 17, 2026
SHA:688166 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 54.51 | 189.17 | 202.47 | 239.62 | 243.95 |
Depreciation & Amortization | 157.87 | 111.41 | 78.06 | 50.47 | 41.5 |
Other Amortization | 12.62 | 9.19 | 10.54 | 11.09 | 10.83 |
Loss (Gain) From Sale of Assets | - | - | - | -0.01 | -0.01 |
Asset Writedown & Restructuring Costs | 9.49 | 8.39 | 1.75 | 1.57 | 0.26 |
Loss (Gain) From Sale of Investments | -0.9 | 11.97 | 12.41 | -3 | -10.02 |
Provision & Write-off of Bad Debts | 19.69 | 11.57 | 0.9 | -2.23 | 10.11 |
Other Operating Activities | 59.96 | 20.46 | 37.19 | -1.08 | 8.27 |
Change in Accounts Receivable | 36.53 | -149.93 | -17.85 | 4.96 | -241.94 |
Change in Inventory | -5.96 | -35.55 | -85.77 | -94.94 | -6.25 |
Change in Accounts Payable | 1.79 | 84.4 | -23.61 | 130.2 | 116.92 |
Change in Other Net Operating Assets | 11.52 | 15.75 | -2.96 | -21.31 | 4.16 |
Operating Cash Flow | 325.19 | 245.56 | 194.77 | 311.26 | 176.08 |
Operating Cash Flow Growth | 32.43% | 26.08% | -37.43% | 76.78% | 13.28% |
Capital Expenditures | -453.41 | -257.2 | -403.76 | -726.73 | -909.66 |
Sale of Property, Plant & Equipment | 0.04 | 0.3 | 0.48 | 0.38 | 0.05 |
Cash Acquisitions | - | - | - | 0.01 | -7.5 |
Investment in Securities | -205.99 | -228.61 | -64.24 | -153.38 | 8.64 |
Other Investing Activities | 36.81 | 45.37 | 31.26 | 18.24 | 18.64 |
Investing Cash Flow | -622.54 | -440.14 | -439.85 | -871.58 | -889.84 |
Long-Term Debt Issued | 1,065 | 823.08 | 678.23 | 1,646 | 882.2 |
Total Debt Issued | 1,065 | 823.08 | 678.23 | 1,646 | 882.2 |
Long-Term Debt Repaid | -870.26 | -804.81 | -569.61 | -474.12 | -210.88 |
Total Debt Repaid | -870.26 | -804.81 | -569.61 | -474.12 | -210.88 |
Net Debt Issued (Repaid) | 194.79 | 18.27 | 108.62 | 1,172 | 671.32 |
Issuance of Common Stock | - | - | - | 219.81 | - |
Repurchase of Common Stock | -10.04 | -10.01 | - | - | - |
Common Dividends Paid | -117.6 | -135.73 | -115.01 | -100.1 | -54.3 |
Other Financing Activities | 430.51 | 103 | 68 | 73 | 86.7 |
Financing Cash Flow | 497.65 | -24.47 | 61.61 | 1,365 | 703.72 |
Foreign Exchange Rate Adjustments | 0.66 | 2.12 | 2.78 | 14.15 | 3.72 |
Net Cash Flow | 200.96 | -216.94 | -180.69 | 818.52 | -6.32 |
Free Cash Flow | -128.22 | -11.64 | -209 | -415.47 | -733.59 |
Free Cash Flow Margin | -10.48% | -0.91% | -17.72% | -40.84% | -69.71% |
Free Cash Flow Per Share | -0.31 | -0.03 | -0.49 | -1.01 | -1.80 |
Cash Income Tax Paid | 18.82 | 25.46 | 29.42 | -17.03 | -7.18 |
Levered Free Cash Flow | -256.49 | -72.62 | -316.64 | -515.42 | -785.87 |
Unlevered Free Cash Flow | -217.14 | -39.85 | -288.87 | -500.6 | -779.81 |
Change in Working Capital | 11.95 | -116.59 | -148.54 | 14.83 | -128.81 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.